{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:12:24Z","timestamp":1788786744800,"version":"build-2803163510"},"reference-count":22,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors increase urinary glucose excretion, but the relationship between glycosuria and findings supporting urinary tract infection (UTI) remains unclear. We evaluated associations of SGLT2 inhibitor use with glycosuria, pyuria, UTI-compatible symptoms, and significant urine culture positivity in adults with type 2 diabetes. Materials and Methods: This prospective cross-sectional study included 251 adults who reported using every agent in their current oral antidiabetic regimen for at least three months. Blood tests, urinalysis, and midstream urine culture were obtained at a single study visit. SGLT2 inhibitor users and nonusers were compared; contaminated cultures were excluded from culture-based analyses. Multivariable logistic regression examined factors associated with glycosuria and pyuria. Results: Overall, 108 participants (43.0%) used an SGLT2 inhibitor (dapagliflozin, n = 51; empagliflozin, n = 57). Glycosuria was more frequent among users than nonusers (69.4% vs. 39.9%; OR = 3.43; 95% CI, 2.02\u20135.82; p &lt; 0.001). In multivariable analysis, SGLT2 inhibitor use (adjusted OR = 3.14; 95% CI, 1.75\u20135.63) and each 1% increase in HbA1c (adjusted OR = 1.56; 95% CI, 1.27\u20131.92) were independently associated with glycosuria. Pyuria and UTI-compatible symptoms did not differ between groups. Among 217 evaluable cultures, significant culture positivity was numerically higher among users, but the estimate was imprecise (9.5% vs. 4.1%; OR = 2.45; 95% CI, 0.79\u20137.57; p = 0.110). Symptomatic culture positivity was similar (4.2% vs. 4.1%; p = 1.000). Conclusions: SGLT2 inhibitor use and higher HbA1c levels were independently associated with glycosuria. The small number of culture-positive events precludes firm conclusions about culture-based outcomes; these analyses are exploratory and do not demonstrate the presence or absence of an association. Glycosuria alone should not be interpreted as an indicator of UTI.<\/jats:p>","DOI":"10.3390\/medicina62091721","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:12:25Z","timestamp":1788783145000},"page":"1721","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of SGLT2 Inhibitor Use with Glycosuria, Pyuria, Urinary Symptoms, and Significant Urine Culture Positivity in Adults with Type 2 Diabetes: A Prospective Cross-Sectional Study"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0603-8731","authenticated-orcid":false,"given":"T\u00fcrkan","family":"T\u00fcz\u00fcn","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Pamukkale University, 20070 Denizli, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6131-0390","authenticated-orcid":false,"given":"Ayten","family":"Erayd\u0131n","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Pamukkale University, 20070 Denizli, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"ref_1","unstructured":"International Diabetes Federation (2025). IDF Diabetes Atlas, International Diabetes Federation. [11th ed.]. Available online: https:\/\/diabetesatlas.org\/resources\/idf-diabetes-atlas-2025\/."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Confederat, L.G., Condurache, M.I., Alexa, R.E., and Dragostin, O.M. (2023). Particularities of urinary tract infections in diabetic patients: A concise review. Medicina, 59.","DOI":"10.3390\/medicina59101747"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40001-022-00644-9","article-title":"The prevalence of urinary tract infections in type 2 diabetic patients: A systematic review and meta-analysis","volume":"27","author":"Salari","year":"2022","journal-title":"Eur. J. Med. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0924-8579(02)00090-0","article-title":"Pathogenesis of bacteriuria in women with diabetes mellitus","volume":"19","author":"Geerlings","year":"2002","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.diabres.2013.12.052","article-title":"Genital and urinary tract infections in diabetes: Impact of pharmacologically induced glucosuria","volume":"103","author":"Geerlings","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e513","DOI":"10.1016\/S1473-3099(23)00778-8","article-title":"A reference standard for urinary tract infection research: A multidisciplinary Delphi consensus study","volume":"24","author":"Bilsen","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1093\/cid\/ciy1121","article-title":"Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America","volume":"68","author":"Nicolle","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Hu, S., Lin, C., Cai, X., Zhu, X., Lv, F., Nie, L., and Ji, L. (2022). The urinary glucose excretion by sodium-glucose cotransporter 2 inhibitor in patients with different levels of renal function: A systematic review and meta-analysis. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.814074"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1038\/s41598-017-02733-w","article-title":"Effects of SGLT2 inhibitors on urinary tract infections and genital infections in type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","article-title":"SGLT-2 inhibitors and the risk of infections: A systematic review and meta-analysis of randomized controlled trials","volume":"55","author":"Puckrin","year":"2018","journal-title":"Acta Diabetol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"E594","DOI":"10.9778\/cmajo.20180111","article-title":"Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections: A systematic review and network meta-analysis of randomized controlled trials","volume":"6","author":"Donnan","year":"2018","journal-title":"CMAJ Open"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/M18-3136","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: A population-based cohort study","volume":"171","author":"Dave","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jcjd.2021.12.005","article-title":"Sodium-glucose cotransporter-2 inhibitors and urinary tract infections: A propensity score-matched population-based cohort study","volume":"46","author":"Alkabbani","year":"2022","journal-title":"Can. J. Diabetes"},{"key":"ref_14","first-page":"1165","article-title":"Asymptomatic pyuria and bacteriuria are not risk factors for urinary tract infection in women with type 2 diabetes mellitus initiated SGLT2 inhibitors","volume":"56","author":"Demir","year":"2024","journal-title":"Int. Urol. Nephrol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"von Elm, E., Altman, D.G., Egger, M., Pocock, S.J., G\u00f8tzsche, P.C., Vandenbroucke, J.P. (2007). The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. PLoS Med., 4.","DOI":"10.1371\/journal.pmed.0040296"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/jdi.13417","article-title":"Clinical and genetic determinants of urinary glucose excretion in patients with diabetes mellitus","volume":"12","author":"Monobe","year":"2021","journal-title":"J. Diabetes Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.2147\/DMSO.S336791","article-title":"The factors influencing the renal glucose threshold in patients with newly diagnosed type 2 diabetes mellitus","volume":"14","author":"Cui","year":"2021","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s13300-024-01613-7","article-title":"Risk of urogenital bacterial infection with sodium-glucose cotransporter-2 inhibitors: A retrospective cohort study using a claims database","volume":"15","author":"Imai","year":"2024","journal-title":"Diabetes Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"945","DOI":"10.2337\/dc24-2169","article-title":"Risk of urogenital infections in people with type 2 diabetes initiating SGLT2is versus GLP-1RAs in routine clinical care: A Danish cohort study","volume":"48","author":"Ljungberg","year":"2025","journal-title":"Diabetes Care"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/10600280241312432","article-title":"Sodium-glucose co-transporter 2 inhibitors and severe urinary tract infections: Real-world meta-analysis of cohort studies","volume":"59","author":"Aboukaoud","year":"2025","journal-title":"Ann. Pharmacother."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes (2026). 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes\u20142026. Diabetes Care, 49, S183\u2013S215.","DOI":"10.2337\/dc26-S009"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3803\/EnM.2024.2120","article-title":"Effectiveness and safety of oral quadruple combination therapy in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"40","author":"Bae","year":"2025","journal-title":"Endocrinol. Metab."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/9\/1721\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:58:10Z","timestamp":1788785890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/9\/1721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":22,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["medicina62091721"],"URL":"https:\/\/doi.org\/10.3390\/medicina62091721","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]}}}